HB 1004 Maryland House of Delegates · 2025 Regular Session

Public Health - Alzheimer's Disease and Related Dementias - Information on Prevalence and Treatment

HB 1004 requires the Maryland Department of Health to incorporate FDA-approved Alzheimer's treatments into public health outreach programs for healthcare providers and the public. It mandates the department to create a publicly accessible website displaying statewide prevalence and hospitalization rates for Alzheimer's and related dementias, disaggregated by age, race, ethnicity, sex, and county. The bill specifically targets improving early detection awareness, emphasizing Medicare wellness visits for seniors, and addressing higher risk in Black and Latino communities. The website must include data from the previous five years and be updated annually starting in 2027.

Issues: ✓ Healthcare

Bill status signed all 5 stages cleared

Introduction

Jan 2025

Committee Review

Mar 2025

House of Delegates Passage

Apr 2025

Senate Passage

Apr 2025

Signed into Law

May 2025

Introduced Jan 31, 2025 Signed May 20, 2025

Maddy AI version diff · 1 comparison

What changed between versions

First - Public Health - Alzheimer's Disease and Related Dementias - Information on Prevalence and Treatment → Third - Public Health - Alzheimer's Disease and Related Dementias - Information on Prevalence and Treatment · 6 edits

MODERATE

The bill was amended to expand data collection requirements on the Alzheimer's disease information website, adding co-occurrence of Down syndrome and type of dementia as new data categories. The sponsor list was updated to include additional delegates, and the bill status was marked as adopted with a favorable committee report. The effective date and core requirements remain unchanged.

REQUIREMENT

Added requirement to include co-occurrence of Down syndrome (Trisomy-21) in the Alzheimer's disease data website

Added requirement to include type of dementia in the Alzheimer's disease data website

Modified Section 18-110 to add 'INCLUDING RELEVANT INFORMATION ON TREATMENT USE AND OUTCOMES' to FDA-approved treatments disclosure

Modified Section 18-110 to add 'INCLUDING INFORMATION RELATED TO TREATMENT OUTCOMES BASED ON BIOLOGICAL SEX' to FDA-approved treatments disclosure

TECHNICAL

Updated sponsor list to include additional delegates (Alston, Bagnall, Bhandari, Cullison, Guzzone, Hill, Hutchinson, S. Johnson, Kaiser, Kerr, Kipke, Lopez, Pena-Melnyk, Reilly, Rosenberg, Ross, Taveras, White Holland, Woods, and Woorman)

Changed document header from 'A BILL ENTITLED' to 'CHAPTER ______' indicating bill has been enacted into law

Floor votes · House of Delegates Mar 8, 2025

How they voted

This bill passed the Senate by voice vote (no roll call recorded).

Full legislative history

Actions timeline

Total actions

Key actions

Committee

May 20, 2025

Signed into law

Approved by the Governor - Chapter 681

executive

Apr 2, 2025

Lower · Passed

Returned Passed

lower

Apr 2, 2025

Upper · Passed

Third Reading Passed

upper

Mar 28, 2025

Upper · Passed

Favorable Adopted Second Reading Passed

upper

Mar 27, 2025

Upper · Passed

Favorable Report by Finance

upper

Mar 17, 2025

Committee

Referred Finance

upper

Mar 17, 2025

Lower · Passed

Third Reading Passed

lower

Mar 15, 2025

Lower · Passed

Favorable with Amendments {

lower

Mar 15, 2025

Lower · Passed

Favorable with Amendments Report by Health and Government Operations

lower

Mar 8, 2025

House Of Delegates · Passed

House of Delegates Vote: pass (127-9-3)

house of delegates

Jan 31, 2025

Committee

First Reading Health and Government Operations

lower

20 primary · 0 co-sponsors